Letrozole

Generic Name
Letrozole
Brand Names
Femara, Kisqali Femara Co-pack
Drug Type
Small Molecule
Chemical Formula
C17H11N5
CAS Number
112809-51-5
Unique Ingredient Identifier
7LKK855W8I
Background

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication

Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.

Associated Conditions
Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Associated Therapies
-
Clinical Trials
Related News

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

First Posted Date
2014-04-02
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
260
Registration Number
NCT02101788
Locations
🇺🇸

Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States

🇺🇸

Saint Joseph Hospital East, Lexington, Kentucky, United States

🇺🇸

Saint Joseph London, London, Kentucky, United States

and more 500 locations

Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men

Phase 4
Completed
Conditions
Obesity
Interventions
Drug: Placebo
Drug: Letrozole
First Posted Date
2014-03-27
Last Posted Date
2022-01-24
Lead Sponsor
University Hospital, Ghent
Target Recruit Count
30
Registration Number
NCT02097680
Locations
🇧🇪

Ghent University Hospital, Ghent, Belgium

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

Not Applicable
Recruiting
Conditions
Breast Cancer
Interventions
Drug: Anastrozole
Drug: Letrozole
First Posted Date
2014-03-24
Last Posted Date
2024-08-05
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
90
Registration Number
NCT02095184
Locations
🇺🇸

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

First Posted Date
2014-03-21
Last Posted Date
2019-10-02
Lead Sponsor
AstraZeneca
Target Recruit Count
79
Registration Number
NCT02093351
Locations
🇬🇧

Research Site, Sutton, United Kingdom

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

First Posted Date
2014-02-06
Last Posted Date
2024-08-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
198
Registration Number
NCT02057133
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States

🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 10 locations

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

Not Applicable
Completed
Conditions
Breast Cancer
Interventions
Drug: Letrozole
First Posted Date
2013-12-12
Last Posted Date
2019-01-17
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
17
Registration Number
NCT02010021
Locations
🇺🇸

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

TRial on the Endocrine Activity of Neoadjuvant Degarelix

First Posted Date
2013-12-09
Last Posted Date
2019-05-29
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
51
Registration Number
NCT02005887
Locations
🇮🇹

Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy

🇮🇹

Istituto Toscana Tumori, Prato, Italy

🇮🇹

Ospedale degli Infermi, Rimini, Italy

and more 4 locations

The Role of Estrogen in Luteinizing Hormone Surge and Ovulation

Phase 4
Completed
Conditions
Ovulation Disorder
Ovarian Cysts
Interventions
Drug: Letrozole
First Posted Date
2013-12-03
Last Posted Date
2022-04-22
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
10
Registration Number
NCT01999569
Locations
🇺🇸

Women's Institute at Carolinas Medical Center, Charlotte, North Carolina, United States

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

First Posted Date
2013-11-21
Last Posted Date
2022-08-04
Lead Sponsor
Japan Breast Cancer Research Group
Target Recruit Count
160
Registration Number
NCT01989780
Locations
🇯🇵

Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)

First Posted Date
2013-10-08
Last Posted Date
2023-04-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
668
Registration Number
NCT01958021
Locations
🇺🇸

Texas Oncology Houston Memorial City SC, Houston, Texas, United States

🇺🇸

City of Hope National Medical Center SC-5, Duarte, California, United States

🇺🇸

Alta Bates Cancer Center Oncology Dept., Berkeley, California, United States

and more 71 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy